[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606191":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":11,"centralContacts":32,"locations":38,"responsibleParty":59,"collaborators":11,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":11,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":11,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":11,"overallStatus":41,"whyStopped":11,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Jiangsu vcare pharmaceutical technology co., LTD","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"VC005 Tablets Low Dose groups","EXPERIMENTAL",null,[13],"Drug: VC005 tablets",{"label":15,"type":10,"description":11,"interventionNames":16},"VC005 Tablets High Dose groups",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"VC005 Tablets Placebo groups","PLACEBO_COMPARATOR",[21],"Drug: VC005 Tablets Placebo",[23,28],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","VC005 tablets","VC005 groups repeat administration for 52 weeks",[15,9],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"VC005 Tablets Placebo","VC005 Placebo groups repeat administration for 52 weeks",[18],[33],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"xiaojuan lai","CONTACT","15358160458","lai_xiaojuan@vcarepharmatech.com",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":11,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"The Peking University People's Hospital","RECRUITING","Beijing","Beijng","China","CN",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},[53,57],{"name":54,"role":35,"phone":55,"phoneExt":11,"email":56},"Jianzhong Zhang","010-88325471","rmzjz@126.com",{"name":54,"role":58,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":60,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100606191","phase-2-efficacy-and-safety-phase-ii-study-of-vc005-tablets-in-subjects-with-non-segmental-vitiligo-100606191",false,"NCT07172347","Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo","A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo","Inclusion Criteria:\n\n* The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.\n* The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.\n\nExclusion Criteria:\n\n* Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.\n* All hair in the vitiligo area on the face is white.\n* Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.\n* Subjects who have previously received depigmentation treatment.\n* Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.","ALL","18 Years","75 Years",{"count":72,"type":73},120,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study",[79],"Non-segmental Vitiligo","2025-12-29",{"date":82,"type":83},"2026-01-02","ACTUAL",{"date":85,"type":83},"2025-10-31",{"date":87,"type":73},"2027-08-30",{"name":5,"class":6},1]